Recent Quotes (30 days)

You have no recent quotes
chg | %

Avivagen Inc  

(Public, CVE:VIV)   Watch this stock  
Find more results for CVE:CFR
0.000 (0.00%)
Dec 2 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.12 - 0.14
52 week 0.04 - 0.22
Open 0.13
Vol / Avg. 250,700.00/659,794.00
Mkt cap 37.50M
P/E     -
Div/yield     -
EPS -0.01
Shares 288.45M
Beta 1.37
Inst. own     -

Key stats and ratios

Q3 (Jul '16) 2015
Net profit margin -1530.32% -1222.15%
Operating margin -1530.32% -1222.14%
EBITD margin - -1209.45%
Return on average assets -161.22% -256.69%
Return on average equity - -
CDP Score - -


100 Sussex Drive
+1-613-9498164 (Phone)
+1-613-9498164 (Fax)

Website links


Avivagen Inc. is a Canada-based development-stage biotechnology company. The Company is engaged in developing science-based, natural health products for animals that are proven in clinical trials. The Company is focused on the development of products from the oxidation of carotenoids based on its OxC-Beta (oxidized carotenoid) technology. It is developing and delivering non-antibiotic feed supplements for optimal livestock productivity. The Company's commercial products are OxC-beta for livestock, Vivamune Health Chews and Oximunol Chewables for dogs and cats. The Company's technologies are based on Natural Health Optimizers (NHOs). The Company has organized into two segments: OxC-Beta product sales and chemistry services sales.

Officers and directors

Cameron Groome President, Chief Executive Officer, Director
Chris Boland Chief Financial Officer
David Hankinson Executive Director
Graham Burton Director - Commercialization Science, Director
David G. P. Allan Director
Vanessa Grant Director
G.F. Kym Anthony Independent Director
Amin I. Khalifa Independent Director